insights_auto
Why is MYGN up 2,62%?
Dive Deeperchevron_right
MYGN:NASDAQ
Myriad Genetics Inc
4,31 US$
arrow_upward
+2,62%(+0,11) 1D
4,31 US$
0,00% (0,00)
bedtimeAfter hours
Closed: 9 ოქტ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MYGN...
Open
4,18 US$
High
4,40 US$
Low
4,15 US$
Mkt. cap
412,25 მლნ.
Avg. vol.
2,03 მლნ.
Volume
1,37 მლნ.
52-wk high
8,59 US$
52-wk low
2,74 US$
EPS
-1,20 US$
Beta
1,64
Shares outstanding
95,65 მლნ.
No. of employees
3 ათ.
Open
4,18 US$
High
4,40 US$
Low
4,15 US$
Mkt. cap
412,25 მლნ.
Avg. vol.
2,03 მლნ.
Volume
1,37 მლნ.
52-wk high
8,59 US$
52-wk low
2,74 US$
EPS
-1,20 US$
Beta
1,64
Shares outstanding
95,65 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
Investing.com
·
3 დღის წინ
Myriad Genetics, SOPHiA partner on prostate cancer biomarker
Profile
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity. Wikipedia
About Myriad Genetics Inc
CEOპოლ ჯეი დიას | პოლ ჯეი დიას
Employees2,7 ათ.
Founded1991
Headquartersსოლტ-ლეიკ-სიტი, იუტა, ამერიკის შეერთებული შტატები
Sector-
Websitemyriad.com